 | | Vol. 15.08 – 2 March, 2023 |
| |
|
|
| Investigators observed that polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) were remarkably enriched in the tumor microenvironment of CCL20-overexpressing cancer cell orthotopic allograft tumors.
[Signal Transduction and Targeted Therapy] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers identified cyclin-dependent kinase 1 (CDK1) and peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) as two previously uncharacterized regulators of protein von Hippel–Lindau (pVHL) in multiple types of human cancers harboring wild-type VHL, including TNBC.
[Cell Death & Differentiation] |
|
|
|
|
| The authors investigated expression of Notch3 in human breast cancer samples and effects of its loss in mice. Notch3 expression was very weak in breast cancer cells and was associated with good patient prognosis.
[Cell Death & Disease] |
|
|
|
| Investigators revealed a novel regulation mechanism by which pellino-1 (PELI1) and epidermal growth factor receptor (EGFR) cooperated to promote breast cancer metastasis.
[Oncogenesis] |
|
|
|
| Researchers investigated the cellular and molecular processes of nanoparticles’ anti-proliferative and apoptotic properties on human breast cancer cells and compared them to the commercial pharmaceutical tamoxifen.
[Scientific Reports] |
|
|
|
| Investigators evaluated the anticancer effect of carotenoids extracted from native Iranian halophilic microorganisms with the ability to inhibit breast cancer cell line. 40 halophilic strains were cultured, and 8 strains capable of producing pigmented colonies were chosen from those cultured strains.
[Cell Biochemistry and Function] |
|
|
|
| Scientists investigated the possibility of selective redox-mediated treatment of TNBC cells by fenbendazole without affecting the viability and redox status of normal breast epithelial cells.
[Anticancer Research] |
|
|
|
| Researchers evaluated the combined effect of monocarboxylate transporter inhibitors and 4-hydroxytamoxifen using the estrogen receptor-positive breast cancer cell line MCF-7, under normal glucose conditions.
[Anticancer Research] |
|  |
|
|
|
| Pre-clinical studies highlighted various antitumor activities of plant-derived Cannabis sativa and synthetic cannabinoids (CBs). However, some studies indicated that CBs might also promote tumor progression. The authors review known and possible interactions between cannabinoids and TNBC therapies.
[Anticancer Research] |
|
|
|
|
| AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
[AstraZeneca] |
|
|
|
|
| April 17 – 19, 2023
Freiburg im Breisgau, Germany |
|
|
|
|
|
| | University of Alberta – Edmonton, Alberta, Canada |
|
|
|
| | University of Oklahoma Health Sciences Center – Oklahoma City, Oklahoma, United States |
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
| | Penn Medicine – Philadelphia, Pennsylvania, United States |
|
|
|
| | University of Texas Health Science Center – San Antonio, Texas United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
